Company Profile

Gilead Sciences Inc (AKA: NeXstar)
Profile last edited on: 11/13/2023      CAGE: 0SFJ8      UEI: FPJMGUK1BYH8

Business Identifier: Biopharmaceutical company developing therapeutics for viral diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

333 Lakeside Drive
Foster City, CA 94404
   (650) 574-3000
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Gilead Sciences Inc. is an independent biopharmaceutical company focused to discovery, development and commercialization of proprietary therapeutics for important viral diseases, including the currently marketed product VISTIDE (cidofovir injection) for the treatment of cytomegalovirus (CMV) retinitis, a sight-threatening viral infection in patients with acquired immune deficiency syndrome (AIDS). The Company received FDA clearance for VISTUDE in June 1996. Many of the Company's products or products in development are nucleotide analogues, including VISTIDE, PREVEON (adefovir dipivoxil), adefovir dipivoxil for hepatitis B and PMPA. Nucleotides exist in every human cell and are the building blocks of the nucleic acids DNA and RNA. In addition, the Company is developing products to treat diseases caused by human immunodeficiency virus (HIV), hepatitis B virus (HBV) and influenza virus, including PREVEON, GS 4104, and PMPA. During the Summer 1999, Gilead merged with NeXstar Pharmaceuticals Inc. NeXstar Pharmaceuticals, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1995 2 NIH $568,858
Project Title: Oligonucleotides Bearing Formacetal Linkages Against HIV
1994 2 NIH $800,000
Project Title: Novel inhibitors of thrombin
1992 1 NIH $50,000
Project Title: Permeation enhanced primer dusrupting antiviral agents
1989 1 NIH $50,000
Project Title: Ribozyme like analogues of oligoribonucleotides

Key People / Management

  John C Martin -- CEO

  John F Milligan -- President and COO

  Norbert W Bischofberger -- EVP, Research & Development

  Chris Alen Buhr

  Mark D Matteucci

  John J Toole